title: Zeroing in on cereblon.
authors.affiliation: Columbia University Medical Center, New York, NY, USA.
authors.forename: Mark L
authors.initials: ML
authors.lastname: Heaney
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D044842:Cullin Proteins / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D010447:Peptide Hydrolases / Q000235:genetics* / Q000378:metabolism; D011485:Protein Binding; D015398:Signal Transduction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D058127:Transcription Factor 3 / Q000235:genetics / Q000378:metabolism; D044767:Ubiquitin-Protein Ligases; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C502543:CRBN protein, human; D002352:Carrier Proteins; C100318:Cullin 1; D044842:Cullin Proteins; D007155:Immunologic Factors; D016328:NF-kappa B; C479529:RBX1 protein, human; D058127:Transcription Factor 3; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D013792:Thalidomide; D044767:Ubiquitin-Protein Ligases; D010447:Peptide Hydrolases; D000077269:Lenalidomide